RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @docjunaid: Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience | Journ…
RT @docjunaid: Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience | Journ…
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience | Journal of Hematology & Oncology | Full Text https://t.co/5iGC1Ov9sC
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @GCC_Cortes: First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
First large US experience with TKI discontinuation in CML published earlier this year. https://t.co/VRWRG2TQ0V
RT @doctorpemm: #TKI discontinuation in patients with CML : a single-institution experience | @kamalchamoun @garciamanero @TapKadia …
RT @doctorpemm: #TKI discontinuation in patients with CML : a single-institution experience | @kamalchamoun @garciamanero @TapKadia …
RT @doctorpemm: #TKI discontinuation in patients with CML : a single-institution experience | @kamalchamoun @garciamanero @TapKadia …
#TKI discontinuation in patients with CML : a single-institution experience | @kamalchamoun @garciamanero @TapKadia @NitinJainMD @doctorpemm @DrHKantarjian Cortes @LeukemiaMDA #leusm https://t.co/RYKqCIggqj
RT @doctorpemm: Tyrosine kinase inhibitor #TKI discontinuation in patients with chronic myeloid leukemia (CML): a single-institution experi…
RT @doctorpemm: Tyrosine kinase inhibitor #TKI discontinuation in patients with chronic myeloid leukemia (CML): a single-institution experi…
Tyrosine kinase inhibitor #TKI discontinuation in patients with chronic myeloid leukemia (CML): a single-institution experience | @LeukemiaMDA @MDAndersonNews #leusm #MPNSM #endcancer https://t.co/RYKqCIggqj
RT @doctorpemm: Our group’s paper now in pubmed ➡️ #TKI 💊discontinuation in patients with CML @LeukemiaMDA | Chamoun @DrHKantarjian @g…
RT @pb10_bmt: MR 4.5 for six years is safe for TKI discontinuation in CML in an @MDAndersonNews single centre study. https://t.co/ElAVi2dt…
MR 4.5 for six years is safe for TKI discontinuation in CML in an @MDAndersonNews single centre study. https://t.co/ElAVi2dtT0 https://t.co/16hHGx3q9I
RT @aamdsif: Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Chamoun…
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Chamoun K, et. al. https://t.co/FavGDE8hHx
RT @doctorpemm: Our group’s paper now in pubmed ➡️ #TKI 💊discontinuation in patients with CML @LeukemiaMDA | Chamoun @DrHKantarjian @g…
RT @doctorpemm: Our group’s paper now in pubmed ➡️ #TKI 💊discontinuation in patients with CML @LeukemiaMDA | Chamoun @DrHKantarjian @g…
RT @doctorpemm: Our group’s paper now in pubmed ➡️ #TKI 💊discontinuation in patients with CML @LeukemiaMDA | Chamoun @DrHKantarjian @g…
RT @doctorpemm: Our group’s paper now in pubmed ➡️ #TKI 💊discontinuation in patients with CML @LeukemiaMDA | Chamoun @DrHKantarjian @g…
RT @doctorpemm: Our group’s paper now in pubmed ➡️ #TKI 💊discontinuation in patients with CML @LeukemiaMDA | Chamoun @DrHKantarjian @g…
RT @doctorpemm: Our group’s paper now in pubmed ➡️ #TKI 💊discontinuation in patients with CML @LeukemiaMDA | Chamoun @DrHKantarjian @g…
RT @doctorpemm: Our group’s paper now in pubmed ➡️ #TKI 💊discontinuation in patients with CML @LeukemiaMDA | Chamoun @DrHKantarjian @g…
Our group’s paper now in pubmed ➡️ #TKI 💊discontinuation in patients with CML @LeukemiaMDA | Chamoun @DrHKantarjian @garciamanero @NitinJainMD @Daver_Leukemia @TapKadia @doctorpemm &Cortes #leusm https://t.co/RYKqCIggqj
TKI discontinuation in patients with CML: https://t.co/ugRNKficNM #CML #TKI #StopTKI #MDAnderson #EndCancer https://t.co/SfvT9J43pM